Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2871

Sigma-Aldrich

Udenafil

≥98% (HPLC)

Synonym(s):

3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide, 3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide, 3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide, 5-[2-Propoxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, 5-[2-Propyloxy-5-(1-methyl-2-pyrrolidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one, DA 8159, DA-8159, DA8159

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H36N6O4S
CAS Number:
268203-93-6
Molecular Weight:
516.66
MDL number:
MFCD20275557
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[S](=O)(=O)(NCCC4N(CCC4)C)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](nc(c3n2)CCC)C)=O

InChI

1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)

InChI key

IYFNEFQTYQPVOC-UHFFFAOYSA-N

Biochem/physiol Actions

Orally active, cGMP-competitive, potent and selective phosphodiesterase type 5 (PDE5) inhibitor with ED and hypertension therapeutic efficacy in vivo.
Udenafil (DA-8159) is an orally active, cGMP-competitive, potent and selective phosphodiesterase type 5 (PDE5) inhibitor (cellular PDE5 activity IC50 = 5.84/8.25 nM in rabbit/human platelets; IC50 = 53.3 nM/PDE6, 870 nM/PDE1, 52 μM/PDE3,101 μM/PDE2). Udenafil shows in vivo therapeutic efficacy in a rat model of monocrotaline-induced pulmonary hypertension (1 or 5 mg/kg bid po.) and induces penile erection in experimental animals in vivo (0.3-10 mg/kg po. in rabbits & rats).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hyounmie Doh et al.
Archives of pharmacal research, 25(6), 873-878 (2003-01-04)
DA-8159, a new Phosphodiesterase (PDE) 5 inhibitor, has exhibited potent erectogenic potential in a penile erection test in rats and anesthetized dogs. In this study, we investigated the mechanism of its erectogenic activity by measuring the activity of DA-8159 against
Kyung Koo Kang et al.
European urology, 43(6), 689-695 (2003-05-28)
DA-8159 is a pyrazolopyrimidinone derivative showing potent and selective phosphodiesterase 5 (PDE5) inhibition. In the previous study, DA-8159 induced a dose-dependent increase in the intracavernous pressure (ICP) in anaesthetized dogs. The aim of this study was to investigate the effects
K K Kang et al.
International journal of impotence research, 17(5), 409-416 (2005-05-28)
This study examined the effects of a new phosphodiesterase type 5 inhibitor, DA-8159, on erectile function associated with hypercholesterolemia. First of all, in order to investigate whether chronic administration of DA-8159 prevents the development of erectile dysfunction associated with hypercholesterolemia
Seong Yul Ryu et al.
The world journal of men's health, 36(1), 41-49 (2017-11-23)
High-fat (HF) feeding induces hypothalamic leptin resistance via the activation of toll-like receptor 4 (TLR4). TLR4 deficiency confers resistance to diet-induced obesity. Udenafil, an anti-impotence drug, inhibits TLR4 in airway epithelial cells in vitro. In this study, we evaluated whether
Kyung Koo Kang et al.
Archives of pharmacal research, 26(8), 612-619 (2003-09-12)
In this study, we evaluated the effects of oral administration of DA-8159, a selective phosphodiesterase-5 inhibitor, on the development of pulmonary hypertension (PH) induced by monocrotaline (MCT). Rats were administered either MCT (60 mg/kg) or saline. MCT-treated rats were divided
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service